| Year |
Citation |
Score |
| 2018 |
Byrd T, Fousek K, Pignata A, Szot C, Samaha H, Dobrolecki L, Oo HZ, Sorensen P, Ellis M, Lewis M, Hegde M, Fletcher B, Croix BS, Ahmed N. Abstract A25: TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A25 |
0.439 |
|
| 2017 |
Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman V, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks JM, Powell S, Baker ML, ... ... Fletcher BS, et al. TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Research. PMID 29183891 DOI: 10.1158/0008-5472.Can-16-1911 |
0.421 |
|
| 2016 |
Byrd T, Fousek K, Pignata A, Szot C, Bielamowicz K, Wakefield A, Koch J, Landi D, Seaman S, Wels W, Fletcher B, Hegde M, Croix BS, Ahmed N. Abstract PD3-07: TEM8 specific CAR T cells serve as a novel targeted therapy for triple negative breast cancer and its supporting endothelium Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd3-07 |
0.443 |
|
| 2015 |
Byrd TT, Fousek K, Grada Z, Aviles-Padilla K, Bielamowicz K, Gottschalk S, Croix BS, Fletcher B, Hegde M, Ahmed N. Abstract B74: Co-targeting the tumor and its associated vasculature in glioblastoma Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B74 |
0.469 |
|
| 2015 |
Byrd T, Fousek K, Pignata A, Szot C, Bielamowicz K, Wakefield A, Seaman S, Fletcher B, Hegde M, Croix BS, Ahmed N. 720. Triple-Negative Breast Cancer Cells and Tumor Endothelium Are Killed by Targeting Tumor Endothelial Marker 8 (TEM8) Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34329-5 |
0.508 |
|
| 2014 |
Byrd T, Fousek K, Grada Z, Aviles-Padilla K, Bielamowicz K, Gottschalk S, Croix BS, Fletcher B, Hegde M, Ahmed N. Abstract LB-264: Two is better than one: Adoptive T cell therapy targeting tumor antigens and the tumor endothelium potentiates T cell activation and cytolytic activity Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-264 |
0.425 |
|
| 2011 |
Gutwein LG, Al-Quran SZ, Fernando S, Fletcher BS, Copeland EM, Grobmyer SR. Tumor endothelial marker 8 expression in triple-negative breast cancer. Anticancer Research. 31: 3417-22. PMID 21965755 |
0.61 |
|
| 2011 |
Grobmyer SR, Morse DL, Fletcher B, Gutwein LG, Sharma P, Krishna V, Frost SC, Moudgil BM, Brown SC. The promise of nanotechnology for solving clinical problems in breast cancer. Journal of Surgical Oncology. 103: 317-25. PMID 21337565 DOI: 10.1002/Jso.21698 |
0.335 |
|
| 2009 |
Fernando S, Fletcher BS. Targeting tumor endothelial marker 8 in the tumor vasculature of colorectal carcinomas in mice. Cancer Research. 69: 5126-32. PMID 19528090 DOI: 10.1158/0008-5472.CAN-09-0725 |
0.606 |
|
| 2009 |
Mátés L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, Grzela DP, Schmitt A, Becker K, Matrai J, Ma L, Samara-Kuko E, Gysemans C, Pryputniewicz D, Miskey C, ... Fletcher B, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nature Genetics. 41: 753-61. PMID 19412179 DOI: 10.1038/Ng.343 |
0.335 |
|
| 2009 |
Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, Rosser CJ. Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. The Prostate. 69: 459-70. PMID 19107861 DOI: 10.1016/S0022-5347(09)61346-X |
0.318 |
|
| 2006 |
Fernando S, Fletcher BS. Sleeping beauty transposon-mediated nonviral gene therapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 20: 219-29. PMID 16831021 DOI: 10.2165/00063030-200620040-00003 |
0.559 |
|
| Show low-probability matches. |